Scientists at Rocky Mountain Laboratories in Hamilton, Montana,conducted a preclinical study of the investigational vaccine AZD1222, their findings were recently published in Nature. AZD122 uses a viral vector to deliver a SARS-CoV-2 spike protein to induce immune response.
See the full news release at Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins (August 31, 2020)
The NIAID COVID-19 Prevention Network (CoVPN) will participate in the Phase 3 clinical trial of AZD1222 in the United States. The CoVPN is composed of existing NIAID-supported clinical research networks with infectious disease expertise and is designed for evaluation of vaccine candidates and antibodies for the prevention of COVID-19.
The Phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by HHS accelerating the development, manufacturing and distribution of medical countermeasures for COVID-19.
“NIH is committed to supporting several Phase 3 vaccine trials to increase the odds that one or more will be effective in preventing COVID-19 and put us on the road to recovery from this devastating pandemic,” said NIH Director Francis S. Collins, M.D., Ph.D.
The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States.